0000919574-25-003241.txt : 20250515 0000919574-25-003241.hdr.sgml : 20250515 20250515153536 ACCESSION NUMBER: 0000919574-25-003241 CONFORMED SUBMISSION TYPE: SCHEDULE 13G/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20250515 DATE AS OF CHANGE: 20250515 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SCHEDULE 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-45385 FILM NUMBER: 25952009 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: SAMLYN CAPITAL, LLC CENTRAL INDEX KEY: 0001421097 ORGANIZATION NAME: EIN: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SCHEDULE 13G/A BUSINESS ADDRESS: STREET 1: 500 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 212-848-0519 MAIL ADDRESS: STREET 1: 500 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 SCHEDULE 13G/A 1 primary_doc.xml SCHEDULE 13G/A 0001421097 XXXXXXXX LIVE 1 Common Stock, $0.0001 par value 03/31/2025 0000906709 Nektar Therapeutics 640268108 455 Mission Bay, Boulevard South San Francisco CA 94158 Rule 13d-1(b) SAMLYN CAPITAL, LLC b DE 0.00 0.00 0.00 0.00 0.00 N 0.0 IA OO SAMLYN, LP b DE 0.00 0.00 0.00 0.00 0.00 N 0.0 PN ROBERT POHLY b X1 0.00 0.00 0.00 0.00 0.00 N 0.0 IN Nektar Therapeutics 455 Mission Bay Boulevard South, San Francisco, California 94158, United States of America Samlyn Capital, LLC Samlyn, LP Robert Pohly Samlyn Capital, LLC 500 Park Avenue, 2nd Floor New York, New York 10022 United States of America Samlyn, LP c/o Samlyn Capital, LLC 500 Park Avenue, 2nd Floor New York, New York 10022 United States of America Robert Pohly c/o Samlyn Capital, LLC 500 Park Avenue, 2nd Floor New York, New York 10022 United States of America Samlyn Capital, LLC - Delaware Samlyn, LP - Delaware Robert Pohly - United States N IA HC Samlyn Capital, LLC - 0 Samlyn, LP - 0 Robert Pohly - 0 Samlyn Capital, LLC - 0.0% Samlyn, LP - 0.0% Robert Pohly - 0.0% Samlyn Capital, LLC - 0 Samlyn, LP - 0 Robert Pohly - 0 Samlyn Capital, LLC - 0 Samlyn, LP - 0 Robert Pohly - 0 Samlyn Capital, LLC - 0 Samlyn, LP - 0 Robert Pohly - 0 Samlyn Capital, LLC - 0 Samlyn, LP - 0 Robert Pohly - 0 N Y N All of the securities reported in this Schedule 13G are directly owned by advisory clients of Samlyn Capital, LLC. None of those advisory clients may be deemed to beneficially own more than 5% of the Common Stock, $0.0001 par value. N Please see Exhibit B attached hereto. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit A - Joint Filing Agreement Exhibit B - Control Person Identification SAMLYN CAPITAL, LLC By: Samlyn, LP, its sole member, By: Samlyn GP, LLC, its general partner, By: /s/ Robert Pohly Robert Pohly, Managing Member* 05/15/2025 SAMLYN, LP By: Samlyn GP, LLC, its general partner, By: /s/ Robert Pohly Robert Pohly, Managing Member* 05/15/2025 ROBERT POHLY /s/ Robert Pohly Robert Pohly* 05/15/2025 * Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his, her or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. EX-99 2 d11785037_ex99-a.htm

 

 

 

Exhibit A

JOINT FILING AGREEMENT

The undersigned agree that this Schedule 13G Amendment No. 1 dated May 15, 2025 relating to the Common Stock, $0.0001 par value, of Nektar Therapeutics shall be filed on behalf of the undersigned.

 

  SAMLYN CAPITAL, LLC
     
  By: Samlyn, LP, its sole member
     
  By: Samlyn GP, LLC, its general partner
     
  By: /s/ Robert Pohly
    Name:  Robert Pohly
    Title:  Managing Member
     
     
  SAMLYN, LP
     
  By: Samlyn GP, LLC, its general partner
     
  By: /s/ Robert Pohly
    Name:  Robert Pohly
    Title:  Managing Member
     
     
  ROBERT POHLY
     
  By: /s/ Robert Pohly
     
 EX-99 3 d11785037_ex99-b.htm

 

 

 

Exhibit B

CONTROL PERSON IDENTIFICATION

Samlyn Capital, LLC is the relevant entity for which Robert Pohly may be considered a control person.